Key result
FibEx clotting time was strongly correlated with edoxaban concentration (r = 0.89) and provided better discrimination for samples with 30 and 50 ng/ml of edoxaban compared to prothrombin time.
Why the study?
Standard aPTT and PT poorly predict the anticoagulant effect of DOACs, motivating evaluation of whether improved clot waveform analysis methods like FibWave could increase sensitivity to edoxaban.
Does the FibWave method improve the detection of clinically relevant edoxaban levels compared to standard aPTT- and PT-based clot waveform analysis in edoxaban-treated patients?
Observational (n=102)
Yes
Does the FibWave method improve the detection of clinically relevant edoxaban levels compared to standard aPTT- and PT-based clot waveform analysis in edoxaban-treated patients?
Effect estimate: r = 0.89 (95% CI 0.83-0.93)
The FibEx assay is more sensitive than standard aPTT- and PT-based clot waveform analysis for detecting clinically relevant anticoagulant levels of edoxaban.
Introduction: The activated partial thromboplastin time (aPTT) and the prothrombin time (PT) are widely available coagulation parameters which are however poor predictors of the anticoagulant effect of direct oral anticoagulants (DOACs). Some coagulometers use the clot waveform analysis (CWA) to assess the clotting time but mainly based on a unique parameter. The improvement of these methodologies and the evaluation of the other waveform parameters may increase the sensitivity to DOACs. Objectives: To assess the performance of an improved clot waveform an method (i.e. FibWave) to detect the impact of edoxaban on the coagulation and the fibrinolytic systems. Methods: ), and 45 control samples were included. The aPTT- and PT-based CWA as well as the FibIn, FibEx, and FibLysis methodologies of the FibWave were implemented and performed on an ACL-TOP 700. Results: = 0.80 and 0.89, respectively). The FibEx clotting time allowed a better discrimination for samples with 30 and 50 ng/ml of edoxaban compared to PT (cutoffs of 96.5 and 114.2 s for the FibEx versus a unique cutoff of 13.1 s for the PT). The fibrinolytic process was impaired in the presence of edoxaban in a dose-dependent manner. Conclusion: FibEx is more sensitive than aPTT- and PT-based CWA for the detection of the clinically relevant anticoagulant level of edoxaban.
No takes yet. Share an insight, caveat, or question.
Evrard et al. (2022) conducted an observational in Edoxaban treatment (n=102). Edoxaban vs. Healthy controls was evaluated on Correlation of FibEx clotting time (time to Max2) with edoxaban concentration (r = 0.89, 95% CI 0.83-0.93). FibEx clotting time was strongly correlated with edoxaban concentration (r = 0.89) and provided better discrimination for samples with 30 and 50 ng/ml of edoxaban compared to prothrombin time.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: